MYASTERIX

"Clinical safety, immunogenicity and efficacy of a therapeutic vaccine that combines peptides mimicking antigen receptors on autoimmune B and T cells associated with myasthenia gravis"

 Coordinatore INSERM - TRANSFERT SA 

 Organization address address: Rue Watt 7
city: PARIS
postcode: 75013

contact info
Titolo: Ms.
Nome: Florence
Cognome: Chung
Email: send email
Telefono: +33 155030122
Fax: +331 55 03 01 60

 Nazionalità Coordinatore France [FR]
 Totale costo 7˙528˙507 €
 EC contributo 5˙900˙720 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-10-01   -   2018-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    INSERM - TRANSFERT SA

 Organization address address: Rue Watt 7
city: PARIS
postcode: 75013

contact info
Titolo: Ms.
Nome: Florence
Cognome: Chung
Email: send email
Telefono: +33 155030122
Fax: +331 55 03 01 60

FR (PARIS) coordinator 375˙360.00
2    CURAVAC EUROPE SPRL

 Organization address address: AVENUE DE VILLEFRANCHE 80
city: RIXENSART
postcode: 1330

contact info
Titolo: Mr.
Nome: Nicolas
Cognome: Havelange
Email: send email
Telefono: +32 486367961

BE (RIXENSART) participant 2˙121˙840.40
3    ACADEMISCH ZIEKENHUIS LEIDEN

 Organization address address: Albinusdreef 2
city: LEIDEN
postcode: 2333 ZA

contact info
Titolo: Prof.
Nome: Jan
Cognome: Verschuuren
Email: send email
Telefono: +31 715262197

NL (LEIDEN) participant 1˙461˙520.00
4    piCHEM Forschungs und Entwicklungsgmbh

 Organization address address: Kahngasse 20
city: Graz
postcode: 8045

contact info
Titolo: Dr.
Nome: Fritz
Cognome: Andreae
Email: send email
Telefono: +43 31668171111
Fax: +43 3166817114

AT (Graz) participant 1˙162˙000.00
5    AEPODIA SA

 Organization address address: RUE LOUIS DE GEER 6
city: OTTIGNIES LOUVAIN LA NEUVE
postcode: 1348

contact info
Titolo: Mrs.
Nome: Charlotte
Cognome: Cuvelier
Email: send email
Telefono: +32 10392013

BE (OTTIGNIES LOUVAIN LA NEUVE) participant 779˙999.60

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

mg    receptors    autoimmune    remission    anti    antibodies    muscle    cell    candidate    model    achr    significant    rate    proof    neuromuscular    antigen    vaccine    therapeutic    peptides    impact    bind    diseases    clinical   

 Obiettivo del progetto (Objective)

'The MYASTERIX project will advance a therapeutic vaccine candidate (designated orphan drug) indicated for the autoimmune disease myasthenia gravis (MG) to clinical proof of concept studies. MG is caused by T cell dependent antibodies that bind to and deplete acetylcholine receptors (AChR) at neuromuscular junctions causing muscle weakness by interfering with neuromuscular transmission and junction architecture. The vaccine candidate comprises two synthetic peptides designed to generate antibodies that bind to autoantibodies and T-cell receptors associated with MG. These peptides prevented or improved muscle fatigue in a rat model of MG and increased the remission rate to 75% in pet dogs (compared to 17% natural remission rate in historical controls). In both models, administration of the peptides resulted in reduced titres of anti-AChR antibodies and lower numbers of anti-AChR T-cells, based on the induction of antibodies that bound to the corresponding B and T cell antigen receptors. These results suggest that similar antigen receptor mimetic vaccination approaches could drive autoimmune diseases like MG into long-term remission. The objectives of the project are to manufacture toxicology and clinical batches of the vaccine human formulation based on already developed and tested standard operating procedures, to carry out stability and regulatory toxicity testing of the GMP product, to conduct phase I and subsequently phase II clinical trials to demonstrate safety, tolerability and proof of mechanism of action/concept of the therapeutic vaccine. The impact on MG patients will be to offer a targeted therapeutic approach requiring only three injections, bringing significant and lasting improvement or even a cure. MG is a model for many autoimmune diseases and the concept of targeted therapeutic vaccines could lead to a new class of drugs for the treatment of autoimmune diseases more generally, with a significant impact on innovation, competitiveness and society.'

Altri progetti dello stesso programma (FP7-HEALTH)

OPTIMISTIC (2012)

"Observational Prolonged Trial In Myotonic dystrophy type 1 to Improve QoL-Standards, a Target Identification Collaboration"

Read More  

TINN2 (2011)

Treat Infections in NeoNates 2 - Evaluation of an infective agent (azithromycin) for the treatment of infections in preterm and term neonates

Read More  

EQUIP (2010)

Expanded Quality management Using Information Power for Maternal and Newborn Health in Africa

Read More